Tenon Medical (TNON) reports Q1 2026 revenue of $1.4M, 90% increase from last year, with gross margin at 68.5%, a record high.

Key Takeaways

• First quarter revenue reached $1.4 million, representing a 90% increase from $0.7 million in the prior year.
• Gross margin for the quarter surged to 68.5%, a significant rise of 24 percentage points year-over-year.
• The company trained 21 physicians across both platforms, indicating increased physician engagement.
• A new $4.3 million senior convertible note placement was successfully closed, extending the company’s financial runway.
• The intellectual property portfolio has expanded to 29 US patents and 9 international patents, enhancing Tenon’s competitive edge.

Financial Performance

In the first quarter of 2026, Tenon Medical, Inc. demonstrated robust financial performance, achieving record revenue and gross profit figures. Revenue for the quarter was $1.4 million, marking a nearly 90% increase compared to $0.7 million in Q1 2025. This growth was primarily driven by two factors: an increase in the number of catamaran surgical procedures and the first full quarter contribution from the recently acquired Symmetry Plus platform.

Gross profit also saw substantial growth, totaling $0.9 million, or 68.5% of revenue. This is a significant improvement from 44.5% in the same quarter last year, amounting to an impressive 193% increase in dollar terms.

Operating expenses were reported at $4.2 million, slightly above the $4.0 million recorded in the first quarter of 2025, primarily due to increased sales and marketing costs related to the Symmetry Plus rollout. Despite the higher expenses, the company narrowed its net loss to $3.5 million, or $0.31 per share, down from a loss of $3.6 million or $1.01 per share a year ago. This improvement reflects the benefits of stronger revenue and gross profit, offsetting the rise in operating costs.

Strategic Initiatives

Tenon Medical is focused on expanding its product offerings and enhancing operational efficiency. The company has seen significant engagement with its two-platform offerings, with physicians using both Kedwin and Symmetry Plus as complementary tools in various surgical procedures.

Notably, Tenon has made strides in its intellectual property portfolio, receiving multiple notices of allowance from the US Patent and Trademark Office during the quarter. With 29 US patents and 9 international patents granted, the company is positioned well to protect its innovations and maintain a competitive advantage in the medical device sector.

In March, Tenon successfully closed a $4.3 million senior convertible note placement, which provides the company with additional financial flexibility to support commercial expansion, product launches, and clinical programs. This financing is crucial as the company aims to aggressively grow procedure volumes across both platforms and enhance training programs for physicians and distributors.

Future Outlook

Looking ahead, Tenon Medical has laid out a clear roadmap for growth. The company plans to continue expanding procedure volumes on both its catamaran and Symmetry Plus platforms. Management remains optimistic about the continued adoption of their technologies, reinforced by positive clinical outcomes and physician feedback.

In addition to maintaining momentum in sales, Tenon is focused on protecting the gross margin gains made this quarter. The management team projects that as revenue scales, further gross margin expansion is expected, potentially reaching 70% in the coming years.

Upcoming product launches are set to be catalysts for growth, with significant additions to the Symmetry Plus platform anticipated in the back half of 2026. Furthermore, the company is preparing for a new regulatory submission related to a third approach to sacral pelvic anatomy, which is expected to enter alpha testing in Q4 2026.

The establishment of a new training and education center in Tampa, Florida, will serve to enhance physician education and improve conversion rates from trials to regular use of Tenon’s products. This strategic move is indicative of the company’s commitment to supporting its physician partners and ensuring successful product adoption.

Overall, Tenon Medical is well-positioned to capitalize on its strong financial performance and strategic initiatives. With a robust balance sheet, an expanding intellectual property portfolio, and a clear focus on growth, the company aims to deliver increasing value to patients, providers, and shareholders alike.

In conclusion, Tenon Medical's first quarter of 2026 has set a solid foundation for continued growth. The company's focus on expanding its product offerings, enhancing operational efficiencies, and training physicians is likely to yield positive results as it continues to execute on its strategic initiatives.

This analysis is based on public earnings call materials and is not investment advice.